Goldman Sachs
MRTX

Goldman Sachs’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Goldman Sachs’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-20,800
Closed -$4.57M – 6423
2020
Q4 		$4.57M Buy
20,800
+19,000
+1,056% +$4.11M ﹤0.01% 3071
2020
Q3 		$299K Hold
1,800
– – ﹤0.01% 4743
2020
Q2 		$206K Buy
+1,800
New +$175K ﹤0.01% 4785
2020
Q1 		– Sell
-31,900
Closed -$4.11M – 5635
2019
Q4 		$4.11M Buy
+31,900
New +$3.08M ﹤0.01% 3119

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Goldman Sachs's MRTX Position: Q1 2024 in Review

Goldman Sachs sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 75,233 shares — an estimated $4.42M sold.

Goldman Sachs first reported a position in MRTX in Q3 2013 and held it in 35 quarters. The position peaked at $164M in Q2 2022. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Goldman Sachs reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Goldman Sachs sold 75,233 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $4.42M.
  • Goldman Sachs first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2013 and held it in 35 quarters.
  • Goldman Sachs's Mirati Therapeutics, Inc. Common Stock position peaked at $164M in Q2 2022.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Goldman Sachs's 13F filing for Q1 2024, filed 15 May 2024.